Editing Oncolytics Biotech Inc.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 61: | Line 61: | ||
* Updated data in advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) from the GOBLET study: H2 2023 | * Updated data in advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) from the GOBLET study: H2 2023 | ||
* Update on the metastatic colorectal and anal cancer cohorts from the GOBLET study: H2 2023 | * Update on the metastatic colorectal and anal cancer cohorts from the GOBLET study: H2 2023 | ||
* Guidance for the registration paths for HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC: H2 2023 | * Guidance for the registration paths for HR+/HER2- metastatic breast cancer and advanced/metastatic PDAC: H2 2023 | ||
=== Core principles / values of the company === | === Core principles / values of the company === |